Objective: To investigate the effect of the H-antihistamine clemastine on the migraine-inducing abilities of pituitary adenylate cyclase activating peptide-38.
Methods: We conducted a double-blind, randomized, placebo controlled two-way cross-over study. Twenty migraine without aura patients were randomly allocated to receive bolus clemastine 2 mg (1 mg/ml) or bolus saline 2 ml intravenously over 2 min on two study days.